On the contrary, drugs that reduce hepatic steatosis, such as PPARα regulators, should be considered with caution in clinical liver surgery, as other studies indicate that genetic or pharmacologic approaches that reduce lipid accumulation may also hinder liver regeneration [63–66]. The gene discussed is PPARA; the disease is fatty liver disease.